Get the Stockscreener App
1.51
0.00%
0.00
Pre-market:
1.47
-0.04
-2.65%
Inmed Pharmaceuticals Inc stock is traded at $1.51, with a volume of 36,103.
It is up +0.00% in the last 24 hours and up +135.90% over the past month.
InMed Pharmaceuticals Inc is a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors. The company's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications.
See More
Previous Close:
$1.51
Open:
$1.54
24h Volume:
36,103
Relative Volume:
0.02
Market Cap:
$5.00M
Revenue:
$3.25M
Net Income/Loss:
$-8.34M
P/E Ratio:
-0.5863
EPS:
-2.5755
Net Cash Flow:
$-7.71M
1W Performance:
-1.95%
1M Performance:
+135.90%
6M Performance:
+25.83%
1Y Performance:
-40.32%
1-Day Range:
$1.49
$1.5501
1-Week Range:
$1.45
$1.60
52-Week Range:
$0.575
$5.50
Inmed Pharmaceuticals Inc Stock (INM) Company Profile
Name
Inmed Pharmaceuticals Inc
Sector
Phone
(604) 669-7207
Address
1445-885 WEST GEORGIA ST., VANCOUVER
Compare INM vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INM
Inmed Pharmaceuticals Inc
|
1.51 | 5.00M | 3.25M | -8.34M | -7.71M | -2.5755 |
TAK
Takeda Pharmaceutical Co Adr
|
15.77 | 49.83B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.07 | 40.04B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.69 | 39.23B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
79.95 | 33.52B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
549.57 | 23.33B | 3.17B | 1.29B | 1.01B | 27.09 |
Inmed Pharmaceuticals Inc Stock (INM) Latest News
InMed-Mentari migraine merger backed by $290 million financing reshapes company strategy (INM) - MSN
Vivo Opportunity funds disclose major InMed (INM) insider share holdings - Stock Titan
Vivo Opportunity Fund Holdings Discloses Investment at InMed Pharmaceuticals with 21.7% Stake - TradingView
InMed Pharmaceuticals Regains Nasdaq Listing Compliance Status - TipRanks
InMed Regains Nasdaq $1.00 Bid-Price Compliance After 10 Consecutive Business Days - TradingView
Nasdaq confirms InMed (NASDAQ: INM) back in minimum bid-price compliance - Stock Titan
Penny stock InMed Pharmaceuticals merger deal targets migraine pipeline - MSN
InMed Pharmaceuticals (INM) Q3 2025 Earnings: Narrower Loss Reported With No Revenue StreamWeak Earnings Momentum - newsline.com
InMed Pharmaceuticals Regains Compliance With Nasdaq Continued Listing Requirements - Moomoo
InMed Pharmaceuticals (INM) Pushes Higher: Testing Resistance at $1.66 After Mild GainsDescending Triangle - newsline.com
ADAR1/Manager Daniel Schneeberger reports 24.1% stake in InMed (NASDAQ: INM) - Stock Titan
InMed Pharmaceuticals regains Nasdaq compliance - Investing.com UK
InMed Pharmaceuticals regains Nasdaq compliance By Investing.com - Investing.com Australia
InMed Pharmaceuticals Regains Compliance with Nasdaq Continued Listing Requirements - TMX Newsfile
Squadron Capital Management LLC Acquires 325,000 Shares in InMed Pharmaceuticals Inc - GuruFocus
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
InMed Highlights INM-901 Alzheimer’s Data in Q3 Update - TipRanks
Squadron Master Fund discloses 9.8% stake in InMed Pharmaceuticals (INM) - Stock Titan
InMed Pharmaceuticals (INM) Shares Slide Over 3% as Biotech Volatility IntensifiesInstitutional Flow Picks - newsline.com
InMed Pharmaceuticals (INM) Holds Steady Near Key Support LevelsSentiment Shift - The Legal Advocate
INM | InMed Pharmaceuticals Inc. Common Insider Trading - Quiver Quantitative
InMed Pharmaceuticals Q3 2025 Earnings: Continued Losses as Stock DeclinesTrough Earnings Signal - Newser
InMed Pharmaceuticals Q3 2025 Earnings: Net Loss Widens Amid Pipeline FocusFree Market Insights - Newser
InMed Pharmaceuticals and Mentari Announce Merger AgreementThe Legal Advocate - The Legal Advocate
InMed Pharmaceuticals Shares Surge Following Mentari Merger Announcement - HarianBasis.co
ADAR1-managed funds add 468,551 InMed (INM) shares in open-market buys - Stock Titan
InMed (INM) major holder ADAR1 reports 331,449 indirect shares on Form 3 - Stock Titan
InMed Pharmaceuticals Merges with Mentari Therapeutics to Target Migraine Prevention - HarianBasis.co
INM Stock Alert: What to Know as InMed, Mentari Announce Merger - Barchart.com
/C O R R E C T I O N -- InMed Pharmaceuticals/ - PR Newswire
Mentari Therapeutics: $290 Million Private Placement Supports Merger With InMed Pharmaceuticals To Advance Migraine Prevention Therapies - Pulse 2.0
InMed Pharmaceuticals (INM) Stock Doubled on Mentari Merger — Why the Rally Is Already Being Tested - TechStock²
Mentari lists via InMed merger, takes $290m for migraine pipeline - The Pharma Letter
InMed Pharmaceuticals Lowers Armistice Preferred Investment Option Exercise Price from $16.60 to $0.80 - Minichart
InMed Pharmaceuticals (INM) Soars 170% on Merger with Mentari Th - GuruFocus
Law firm investigates InMed Pharmaceuticals' board over possible unfair sale to Mentari Therapeutics - Pluang
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of InMed Pharmaceuticals, Inc. (Nasdaq – INM) - GlobeNewswire
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of InMed Pharmaceuticals, Inc. (Nasdaq – INM) - GlobeNewswire Inc.
Mentari, InMed Merge In Deal Backed By $290M Funding - Law360
InMed Pharmaceuticals, Inc. (INM) Stock: Climbs on $290M Private Placement and Migraine Pipeline Deal - parameter.io
InMed Pharmaceuticals and Mentari Therapeutics Announce $290M Merger to Advance Migraine Prevention Therapies - Minichart
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
InMed amends warrant terms, cuts exercise price to $0.80 - Investing.com UK
InMed Soars 100% on $290M Migraine Deal - TechStock²
InMed Pharmaceuticals (INM) Merges with Mentari Therapeutics for Migraine Treatment Development - GuruFocus
Trending Stocks Today | Amesite Surges 150.6% - Moomoo
Inmed Pharmaceuticals Inc Stock (INM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Inmed Pharmaceuticals Inc Stock (INM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Vivo Opportunity, LLC | 10% Owner |
Jun 05 '26 |
Buy |
1.57 |
55,011 |
86,367 |
688,926 |
| Vivo Opportunity, LLC | 10% Owner |
May 21 '26 |
Buy |
1.69 |
34,000 |
57,460 |
574,011 |
| Vivo Opportunity, LLC | 10% Owner |
Jun 08 '26 |
Buy |
1.52 |
32,500 |
49,400 |
718,444 |
| Vivo Opportunity, LLC | 10% Owner |
Jun 02 '26 |
Buy |
1.52 |
22,848 |
34,729 |
625,766 |
| Vivo Opportunity, LLC | 10% Owner |
May 29 '26 |
Buy |
1.57 |
17,796 |
27,940 |
590,175 |
| Vivo Opportunity, LLC | 10% Owner |
Jun 01 '26 |
Buy |
1.55 |
16,336 |
25,321 |
605,013 |
| Vivo Opportunity, LLC | 10% Owner |
Jun 03 '26 |
Buy |
1.55 |
7,783 |
12,064 |
632,835 |
| Vivo Opportunity, LLC | 10% Owner |
Jun 04 '26 |
Buy |
1.57 |
6,743 |
10,587 |
638,960 |
| ADAR1 Capital Management, LLC | 10% Owner |
May 19 '26 |
Buy |
1.54 |
468,551 |
721,548 |
800,000 |
9.24%
0.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):